India hopes to get Hyderabad-based Biological E’s indigenous COVID-19 vaccine by August this year. Biological E Ltd is done with phase 1 and phase 2 trials. Now, they are ready for phase 3 trails.
“Phase 1, phase 2 trials of Indian vaccine of Biological E have finished and they’ll soon go into phase 3. This is a very significant development as they have a capacity of 7 crore/ 70 million vaccines per month,” NITI Aayog member Dr VK Paul said today.
Biological E Ltd will manufacture 1 billion doses of Covid-19 vaccines including the one developed by Johnson & Johnson under the Quad Vaccine Partnership, a White House press note had earlier said.
“The United States, through the DFC (Development Finance Corporation), will work with Biological E Ltd, to finance increased capacity to support Biological E’s effort to produce at least 1 billion doses of Covid-19 vaccines by the end of 2022 with Stringent Regulatory Authorization (SRA) and/or World Health Organization (WHO) Emergency Use Listing (EUL), including the Johnson & Johnson vaccine,” the statement said.
Along with the Serum Institute and Bharat Biotech, the firm has been one of the most active vaccine developers from India during the pandemic, developing a protein subunit vaccine developed by US-based Baylor College of Medicine and mass manufacturing another by Johnson & Johnson.
Biological E Ltd is the largest manufacturer of tetanus vaccines and snake venom antidotes in India.
Surjitt Sahani
